# Skin lesions in patients treated with growth hormone and those with growth hormone excess: a current overview

**Authors:** Mateusz Matwiejuk, Hanna Myśliwiec, Agnieszka Miklosz, Adrian Chabowski, Iwona Flisiak

PMC · DOI: 10.3389/fmed.2026.1777658 · Frontiers in Medicine · 2026-03-12

## TL;DR

This paper reviews skin conditions caused by growth hormone excess or treatment, explaining their causes and current management strategies.

## Contribution

The paper provides a current overview of skin manifestations in GH excess and treatment, summarizing recent management findings.

## Key findings

- GH excess or treatment leads to skin thickening, oily skin, and skin tags due to GH and IGF-1 effects.
- Current therapies for managing these skin lesions have benefits but also notable side effects and limitations.
- Skin changes are common in disorders like acromegaly and gigantism, affecting patients' quality of life.

## Abstract

Growth hormone (GH) is an ancestral hormone secreted from the anterior pituitary gland. In adulthood, it is essential to regulate metabolism. GH synthesis and secretion are regulated in a complex manner, primarily through the actions of hypothalamic neuropeptides (GHRH and somatostatin) that integrate hormonal, metabolic, and neurogenic signals. Currently, recombinant human GH is widely used to treat growth hormone deficiency (GHD) and numerous non-GHD disorders, such as short stature and catabolic conditions. Conversely, an excess of GH may lead to different and severe conditions, such as acromegaly, gigantism, Carney complex, McCune–Albright syndrome, neurofibromatosis, and multiple endocrine neoplasia type 1. In patients with growth hormone excess disorders or those treated with GH, skin manifestations are common and can include skin thickening, coarsened facial features, skin tags, oily skin, and excessive sweating. These dermatological changes result from the direct actions of GH and IGF-1 (insulin-like growth factor 1) on skin cells and appendages, leading to increased collagen synthesis and connective tissue expansion. This review focuses on the various skin symptoms associated with these disorders caused by GH excess. This narrative review summarizes recent findings on the management of skin lesions in GH-treated patients and in those with GH excess, highlighting the benefits, side effects, and limitations of current therapies.

## Linked entities

- **Proteins:** GHRH (growth hormone releasing hormone), GH1 (growth hormone 1), IGF1 (insulin like growth factor 1)
- **Diseases:** acromegaly (MONDO:0019933), gigantism (MONDO:0020479), Carney complex (MONDO:0015285), McCune–Albright syndrome (MONDO:0018919), neurofibromatosis (MONDO:0018975), multiple endocrine neoplasia type 1 (MONDO:0007540)

## Full-text entities

- **Genes:** SST (somatostatin) [NCBI Gene 6750] {aka SMST, SST1}, GHRH (growth hormone releasing hormone) [NCBI Gene 2691] {aka GHRF, GRF, INN}, GGH (gamma-glutamyl hydrolase) [NCBI Gene 8836] {aka GATD10, GH}, IGF1 (insulin like growth factor 1) [NCBI Gene 3479] {aka IGF, IGF-I, IGFI, MGF}, GH1 (growth hormone 1) [NCBI Gene 2688] {aka GH, GH-N, GHB5, GHN, IGHD1A, IGHD1B}
- **Diseases:** growth hormone excess (MESH:C531600), Carney complex (MESH:D056733), short stature (MESH:D006130), Skin lesions (MESH:D012871), GHD (MESH:D004393), multiple endocrine neoplasia type 1 (MESH:D018761), McCune-Albright syndrome (MESH:D005359), neurofibromatosis (MESH:D017253), gigantism (MESH:D005877), acromegaly (MESH:D000172)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13017247/full.md

## References

39 references — full list in the complete paper: https://tomesphere.com/paper/PMC13017247/full.md

---
Source: https://tomesphere.com/paper/PMC13017247